

Lubos Petruzelka

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4500832/lubos-petruzelka-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

97 papers	7,223 citations	35 h-index	84 g-index
126 ext. papers	8,467 ext. citations	5 avg, IF	4.83 L-index

#	Paper	IF	Citations
97	Immunomodulation with β -glucan from in patients with endocrine-dependent breast cancer. <i>Immunotherapy</i> , 2022 , 14, 31-40	3.8	1
96	Ex Vivo Vibration Spectroscopic Analysis of Colorectal Polyps for the Early Diagnosis of Colorectal Carcinoma. <i>Diagnostics</i> , 2021 , 11,	3.8	1
95	Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice. <i>Targeted Oncology</i> , 2020 , 15, 193-201	5	3
94	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3638-3651	2.2	47
93	Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients. <i>Cancer Management and Research</i> , 2020 , 12, 5365-5372	3.6	4
92	Serum levels of TIMP-1 and MMP-7 as potential biomarkers in patients with metastatic colorectal cancer. <i>International Journal of Biological Markers</i> , 2019 , 34, 292-301	2.8	14
91	Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in Mutation Carriers Versus Non-Carriers. <i>Cancers</i> , 2019 , 11,	6.6	12
90	Novel serum markers HSP60, CHI3L1, and IGFBP-2 in metastatic colorectal cancer. <i>Oncology Letters</i> , 2019 , 18, 6284-6292	2.6	12
89	Growth/differentiation factor 15 (GDF-15) as new potential serum marker in patients with metastatic colorectal cancer. <i>Cancer Biomarkers</i> , 2018 , 21, 869-874	3.8	23
88	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018 , 391, 2128-2139	40	910
87	Anthracycline antibiotics derivate mitoxantrone-Destructive sorption and photocatalytic degradation. <i>PLoS ONE</i> , 2018 , 13, e0193116	3.7	5
86	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. <i>Lancet Oncology, The</i> , 2018 , 19, 27-39	31.7	413
85	MABp1 as a novel antibody treatment for advanced colorectal cancer: a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2017 , 18, 192-201	21.7	103
84	Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges. <i>Trends in Cancer</i> , 2017 , 3, 391-406	12.5	161
83	Molecular characterization and heterogeneity of circulating tumor cells in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 166, 695-700	4.4	23
82	Molecular pathological predictive diagnostics in a patient with non-small cell lung cancer treated with crizotinib therapy: A case report. <i>Oncology Letters</i> , 2017 , 14, 7545-7548	2.6	2
81	Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry. <i>Targeted Oncology</i> , 2017 , 12, 89-95	5	13

80	5-fluorouracil Toxicity Mechanism Determination in Human Keratinocytes: in vitro Study on HaCaT Cell Line. <i>Prague Medical Report</i> , 2017 , 118, 128-138	0.7	1
79	Immunomonitoring in patients with stage II and III colon cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e23038-e23038	2.2	
78	Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu- positive advanced breast cancer: results of the CECOG LaVie trial. <i>BMC Cancer</i> , 2016 , 16, 121	4.8	4
77	Modified FOLFIRINOX in the treatment of pancreatic cancer Efficiency and toxicity. <i>Gastroenterologie A Hepatologie</i> , 2016 , 70, 413-417	1.4	2
76	Plasma Phosphatidylcholines Fatty Acids in Men with Squamous Cell Esophageal Cancer: Chemoradiotherapy Improves Abnormal Profile. <i>Medical Science Monitor</i> , 2016 , 22, 4092-4099	3.2	5
75	Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: general hospital cancer center experience. <i>Neoplasma</i> , 2016 , 63, 269-73	3.3	36
74	Complete diagnostics and clinical approach for a female patient with unusual glioblastoma: A case study. <i>Molecular and Clinical Oncology</i> , 2016 , 5, 161-164	1.6	1
73	Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1230-9	21.7	42
72	The minimizing of fluorescence background in Raman optical activity and Raman spectra of human blood plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2015 , 407, 1335-42	4.4	18
71	The potential of chiroptical and vibrational spectroscopy of blood plasma for the discrimination between colon cancer patients and the control group. <i>Analyst, The</i> , 2015 , 140, 2287-93	5	17
70	Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study. <i>Targeted Oncology</i> , 2015 , 10, 557-63	5	7
69	Predictive factors for the presence of tumor cells in bone marrow and peripheral blood in breast cancer patients. <i>Neoplasma</i> , 2015 , 62, 259-68	3.3	6
68	Trefoil factor family (TFF) proteins as potential serum biomarkers in patients with metastatic colorectal cancer. <i>Neoplasma</i> , 2015 , 62, 470-7	3.3	16
67	The protective effect of pyrimidine nucleosides on human HaCaT keratinocytes treated with 5-FU. <i>Anticancer Research</i> , 2015 , 35, 1303-10	2.3	4
66	Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry. <i>Anticancer Research</i> , 2015 , 35, 3455-61	2.3	3
65	Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. <i>British Journal of Cancer</i> , 2014 , 111, 2051-7	8.7	20
64	Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy. <i>Neoplasma</i> , 2014 , 61, 90-98	3.3	9
63	Raman spectroscopy at different excitation wavelengths (1064, 785 and 532 nm) as a tool for diagnosis of colon cancer. <i>Journal of Raman Spectroscopy</i> , 2014 , 45, 903-911	2.3	37

62	Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases. <i>Molecular Medicine Reports</i> , 2014 , 10, 2669-74	2.9	8
61	Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. <i>Journal of the National Cancer Institute</i> , 2014 , 106, djt337	9.7	181
60	Serum adiponectin relates to shortened overall survival in men with squamous cell esophageal cancer treated with preoperative concurrent chemoradiotherapy: a pilot study. <i>Medical Science Monitor</i> , 2014 , 20, 2351-7	3.2	8
59	Analysis of human blood plasma and hen egg white by chiroptical spectroscopic methods (ECD, VCD, ROA). <i>Analytical and Bioanalytical Chemistry</i> , 2013 , 405, 5441-53	4.4	20
58	Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. <i>Lancet, The</i> , 2013 , 381, 805-16	4.0	1293
57	Breast cancer characteristics-comparison of preoperative and postoperative values. <i>Pathology Research and Practice</i> , 2013 , 209, 433-40	3.4	0
56	Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. <i>Lancet Oncology, The</i> , 2013 , 14, 125-33	21.7	93
55	Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 149-55	4.4	10
54	Predicting axillary sentinel node status in patients with primary breast cancer. <i>Neoplasma</i> , 2013 , 60, 334-42	3.3	9
53	Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLECTRA trial. <i>Breast</i> , 2012 , 21, 27-33	3.6	160
52	The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. <i>Breast Cancer Research and Treatment</i> , 2012 , 131, 295-306	4.4	8
51	Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. <i>Lancet Oncology, The</i> , 2012 , 13, 420-32	21.7	52
50	Plasma fatty acid composition in patients with pancreatic cancer: correlations to clinical parameters. <i>Nutrition and Cancer</i> , 2012 , 64, 946-55	2.8	35
49	An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012 , 48, 324-32	7.5	70
48	Local treatment of hand-foot syndrome with uridine/thymidine: in vitro appraisal on a human keratinocyte cell line HaCaT. <i>Scientific World Journal, The</i> , 2012 , 2012, 421325	2.2	1
47	Postoperative radiochemotherapy with weekly cisplatin in patients with head and neck cancer single-institution outcome analysis. <i>Neoplasma</i> , 2012 , 59, 129-36	3.3	3
46	Apoptosis - associated genes and their role in predicting responses to neoadjuvant breast cancer treatment. <i>Medical Science Monitor</i> , 2012 , 18, BR60-67	3.2	9
45	PET/CT significance for planning radiotherapy of head and neck cancer. <i>Neoplasma</i> , 2012 , 59, 536-40	3.3	7

44	Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 159-74	4	14
43	Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. <i>Annals of Oncology</i> , 2012 , 23, 1214-1222	10.3	75
42	Abstract S1-4: Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg 2012 ,		7
41	Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8 years median follow-up. <i>Lancet Oncology</i> , 2011 , 12, 1101-8	21.7	298
40	Novel therapeutic targets in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2011 , 6, 1601-12	8.9	110
39	Sentinel lymph node biopsy in breast cancer patients treated with neoadjuvant chemotherapy. <i>Cancer</i> , 2011 , 117, 4606-16	6.4	32
38	Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). <i>Annals of Oncology</i> , 2011 , 22, 1154-1163	10.3	134
37	Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up. <i>Ecological Management and Restoration</i> , 2010 , 23, 160-7	3	19
36	Population-based study of BRCA1/2 mutations: family history based criteria identify minority of mutation carriers. <i>Neoplasia</i> , 2010 , 57, 280-5	3.3	6
35	Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4594-600	2.2	467
34	Activity of fulvestrant in HER2-overexpressing advanced breast cancer. <i>Annals of Oncology</i> , 2010 , 21, 1246-1253	10.3	19
33	Third consensus on medical treatment of metastatic breast cancer. <i>Annals of Oncology</i> , 2009 , 20, 1771-85	10.3	139
32	Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. <i>Annals of Oncology</i> , 2009 , 20, 1489-1498	10.3	136
31	Presentation, management and outcome of 32 patients with pregnancy-associated breast cancer: a matched controlled study. <i>Breast Journal</i> , 2009 , 15, 461-7	1.2	64
30	Design, conduct, and analyses of Breast International Group (BIG) 1-98: a randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer. <i>Clinical Trials</i> , 2009 , 6, 272-87	2.2	31
29	Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. <i>Lancet Oncology</i> , 2009 , 10, 147-54	21.7	247
28	Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5569-75	2.2	262
27	Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. <i>Cancer Investigation</i> , 2007 , 25, 720-5	2.1	82

26	Second consensus on medical treatment of metastatic breast cancer. <i>Annals of Oncology</i> , 2007 , 18, 215-25.3	83
25	A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 7071-8	12.9 10
24	Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. <i>British Journal of Cancer</i> , 2006 , 95, 788-93	8.7 50
23	Breast cancer risk assessment in the Czech female population--an adjustment of the original Gail model. <i>Breast Cancer Research and Treatment</i> , 2006 , 95, 29-35	4.4 30
22	High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. <i>Breast Cancer Research</i> , 2005 , 7, R728-36	8.3 53
21	KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients. <i>Melanoma Research</i> , 2005 , 15, 251-6	3.3 34
20	Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma. <i>Supportive Care in Cancer</i> , 2005 , 13, 760-2	3.9 16
19	The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic. <i>Breast Cancer Research and Treatment</i> , 2005 , 90, 165-7	4.4 31
18	Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. <i>Lung Cancer</i> , 2004 , 46, 87-98	5.9 351
17	Report on the first patient group of the phase I BNCT trial at the LVR-15 reactor. <i>International Congress Series</i> , 2004 , 1259, 27-32	7
16	Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy: results from an expanded access programme. <i>European Journal of Cancer, Supplement</i> , 2004 , 2, 132-133	1.6 10
15	Dietary habits and lung cancer risk among non-smoking women. <i>European Journal of Cancer Prevention</i> , 2004 , 13, 471-80	2 53
14	Phase II multicentre trial of ZD9331 monotherapy as first-line treatment for gastric cancer. <i>Anti-Cancer Drugs</i> , 2003 , 14 Suppl 1, S7-12	2.4 4
13	Mutations of the BRCA1 gene in hereditary breast and ovarian cancer in the Czech Republic. <i>Medical Principles and Practice</i> , 2003 , 12, 23-9	2.1 22
12	Role of Taxanes. <i>Breast Cancer Research and Treatment</i> , 2003 , 81, 17-24	4.4 1
11	Consensus on Medical Treatment of Metastatic Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003 , 81, 1-7	4.4 31
10	Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. <i>British Journal of Cancer</i> , 2003 , 89 Suppl 2, S19-23	8.7 20
9	Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIB and IV non-small cell lung cancer: a phase III randomized trial. <i>Lung Cancer</i> , 2003 , 41, 321-31	5.9 140

8	Adenocarcinoma of the lung among women: risk associated with smoking, prior lung disease, diet and menstrual and pregnancy history. <i>Lung Cancer</i> , 2003 , 41, 283-93	5.9	42
7	Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study. <i>Expert Opinion on Pharmacotherapy</i> , 2003 , 4, 581-6	4	7
6	Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. <i>Annals of Oncology</i> , 2003 , 14, 1383-90 ^{10.3}		37
5	Large expansion of morphologically heterogeneous mammary epithelial cells, including the luminal phenotype, from human breast tumours. <i>Breast Cancer Research and Treatment</i> , 2002 , 71, 219-35	4.4	12
4	Lung cancer risk among Czech women: a case-control study. <i>Preventive Medicine</i> , 2002 , 34, 436-44	4.3	48
3	Gemcitabine/carboplatin in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2002 , 38 Suppl 2, S33-6	5.9	22
2	Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. <i>Lung Cancer</i> , 1998 , 22, 243-50	5.9	19
1	In vivo dosimetry with the use of silicon photodiodes. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 1988 , 127, 1-5	1.5	